Back to results
US 2013/0210857 A1Published application
Inhibitors of Human Immunodeficiency Virus Replication
AssigneeBristol-Myers Squibb Company
InventorsMichael A. Walker, Margaret E. Sorenson, B. Narasimhulu Naidu, Kevin Peese, Barry L. Johnson, Manoj Patel
Life of this patent
Estimating the term…
Abstract
The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
Claims15
A compound of Formula I
- where:
- R1 is hydrogen, alkyl, cycloalkyl, haloalkyl, (Ar2)alkyl, (Ar2)cycloalkyl, Ar2, alkylCO, cycloalkylCO, haloalkylCO, (Ar2)alkylCO, ((Ar2)cycloalkyl)alkylCO, (Ar2)cycloalkylCO, Ar2CO, (Ar2)alkylCOCO, Ar2COCO, alkylCO2, haloalkylCO2, (Ar2)alkylCO2, Ar2CO2, alkylCONH, haloalkylCONH, (Ar2)alkylCONH, Ar2CONH, alkylSO2, cycloalkylSO2, haloalkylSO2, and Ar2SO2;
- or R1 is (PhCH2O)PhCH2CO,
- R2 is alkyl or haloalkyl;
- R3 is alkyl;
- R4 is hydrogen or alkyl;
- R5 is hydrogen or alkyl;
- Ar1 is phenyl or chromanyl, and is substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, alkoxy, and haloalkoxy;
- and
- Ar2 is phenyl, biphenyl, or indolyl, and is substituted with 0-3 substituents selected from halo, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, and haloalkoxy;
- or a pharmaceutically acceptable salt thereof.
8 more elements
Dependencies are inferred from the claim text.